Avaxia Biologics

Avaxia is an early-stage biotechnology company focused on developing recombinant, gut-targeted antibody therapeutics for gastrointestinal diseases. These unique antibody therapeutics, called Avaximabs™, are orally administered, minimally absorbed drugs that act locally in the gastrointestinal (GI) tract. Avaxia believes that treatment of GI diseases with gut-targeted antibodies has the potential to address important limitations of existing therapies.